{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:26:37Z","timestamp":1792207597463,"version":"4.4.0"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Acalabrutinib, a Bruton tyrosine kinase inhibitor, demonstrated greater selectivity and improved safety versus ibrutinib in a head\u2010to\u2010head trial in relapsed\/refractory (R\/R) chronic lymphocytic leukaemia. In the R\/R marginal zone lymphoma (MZL) cohort (phase 2) of a phase 1b\/2 trial (NCT02180711), 43 patients with MZL and\u2009at least one prior therapy received acalabrutinib 100\u2009mg twice daily until disease progression or unacceptable toxicity [median age 69 years (range 42\u201384); median one (1\u20134) prior systemic regimens]. Median follow\u2010up was 13.3\u00a0months (range 0.5\u201345.5). Among 40 patients evaluable for response, investigator\u2010assessed overall response rate was 53% [95% confidence interval (CI) 36%\u201369%] with five (13%) complete responses. Tumour reduction occurred in 40 (93%) of the treated patients. Median time to response was 2.9\u00a0months (median duration of response not estimable). Estimated median progression\u2010free survival (PFS) was 27.4\u00a0months (12\u2010month PFS rate, 67%). Five patients died (disease progression, n\u00a0=\u00a04; septic shock, n\u00a0=\u00a01). Seventeen patients (40%) had grade\u00a03 or higher adverse events (AEs), most commonly neutropenia (14%), anaemia, dyspnoea (7% each), fatigue and thrombocytopenia (5% each). Hypertension occurred in 5%; atrial fibrillation\/flutter and major haemorrhage were not reported. AEs led to treatment discontinuation in three (7%) patients. Acalabrutinib was active and well tolerated in patients with R\/R MZL.<\/jats:p>","DOI":"10.1111\/bjh.18368","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T12:04:22Z","timestamp":1658405062000},"page":"76-85","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["A phase 2, multicentre, open\u2010label trial (<scp>ACE\u2010LY<\/scp>\u2010003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma"],"prefix":"10.1111","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-1459","authenticated-orcid":false,"given":"Paolo","family":"Strati","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[{"name":"Clinical Research Alliance\/Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Champion","sequence":"additional","affiliation":[{"name":"Norton Cancer Institute  Louisville Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[{"name":"A.O.O.R. Villa Sofia\u2010Cervello, U. O. C. Oncoematologia  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe Y.","family":"Levy","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"University of Miami\u2212Miller School of Medicine  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Ramakrishnan","family":"Geethakumari","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selay","family":"Lam","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Calvo","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Higgins","sequence":"additional","affiliation":[{"name":"AstraZeneca  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[{"name":"City Of Hope National Medical Center  Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"National Cancer InstituteSEER incidence rates and annual percent change by age at diagnosis. Bethesda MD: National Cancer Institute. 2020 [cited April 2020]. Available from:https:\/\/seer.cancer.gov\/archive\/csr\/1975_2017\/"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.010"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/aol-20-20"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01072-6"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-747345"},{"key":"e_1_2_9_8_1","unstructured":"Imbruvica [package insert]. Sunnyvale CA Horsham PA: Pharmacyclics Janssen Biotech Inc.; May 2022"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1704"},{"key":"e_1_2_9_10_1","unstructured":"Brukinsa [package insert]. San Mateo CA: BeiGene USA Inc; September 2021."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"e_1_2_9_12_1","unstructured":"Calquence [package insert]. Wilmington DE: AstraZeneca Pharmaceuticals; November 2019."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16118"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2043301"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278654"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","unstructured":"WangM RobakT MaddocksKJ PhillipsT SmithSD GallinsonD CalvoR WunCC MunugalavadlaV JurczakWSafety and efficacy of acalabrutinib plus venetoclax and rituximab in patients with treatment\u2010naive mantle cell lymphoma [poster 2416]. Annual meeting and exposition of the American Society of Hematology; 11\u201014 December 2021; Atlanta GA 138 2416","DOI":"10.1182\/blood-2021-146615"},{"key":"e_1_2_9_18_1","unstructured":"PhillipsT SmithSD JurczakW RobakT StevensDA FarberCM PagelJM MaddocksK FlinnI JedrzejczakWW GoyA ZinzaniPL ZauchaJ ColemanM ChenT LeeSK LiangW SetoA WangMSafety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment\u2010naive or relapsed\/refractory mantle cell lymphoma [poster MCL\u2010194]. Annual meeting of the Society of Hematological Oncology; 11\u201014 September 2019; Houston TX.19 S317"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00909-1"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780442"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88737"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003121"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03433"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-720599"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18368","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18368","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T08:30:52Z","timestamp":1692606652000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/bjh.18368"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18368","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"2022-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}